Press Releases ContraFect Corporation

Equities

CFRXQ

US2123264093

Market Closed - OTC Markets Other stock markets 20:20:39 30/04/2024 BST			5-day change	1st Jan Change
0.0157 ^USD	+4.40%		-17.80%	-47.67%

04-26	North American Morning Briefing : Tech Still in -2-	DJ
04-19	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ContraFect: Q3 Earnings Snapshot	11-14	AQ
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study	16/10/23	AQ
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development	19/09/23	AQ
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370	18/09/23	AQ
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023	28/08/23	AQ
ContraFect : Q2 2023 Investor Presentation	15/08/23	PU
ContraFect: Q2 Earnings Snapshot	14/08/23	AQ
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update	14/08/23	AQ
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million	27/06/23	AQ
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	20/06/23	AQ
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens	20/06/23	AQ
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023	08/06/23	AQ
CONTRAFECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	16/05/23	AQ
ContraFect: Q1 Earnings Snapshot	15/05/23	AQ
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update	15/05/23	AQ
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	26/04/23	AQ
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens	20/04/23	AQ
CONTRAFECT CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	18/04/23	AQ
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting	06/04/23	AQ
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	03/04/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ContraFect Corporation

Equities

CFRXQ

US2123264093

Press Releases

Filters